HORIZONS



Understanding the impact of cancer diagnosis and treatment on everyday life

24 MONTH OVARIAN CANCER CRF

(please also use for primary peritoneal and fallopian tube cancers)

FOR STAFF USE ONLY

CRF Completion Instructions

- Please complete as much of the CRF as possible
- Please refer to your copies of previous CRFs when completing this 24 month CRF: please complete any additional treatment details that were not captured at 6 or 12 months (for example, additional treatments, or end dates of those ongoing in earlier CRFs)
- If you have any queries, please contact the HORIZONS
 Co-ordinating Centre, email address <u>HORIZONS@soton.ac.uk</u>
- Please tick boxes when appropriate
- When you have completed the CRF, please keep a copy for your own records and return a copy to us, by post, fax or email along with the completed return cover sheet

©2025. This work is openly licensed by CC BY-NC-SA

Participant's Study ID]/[/						
Participant's date of birth	d	d	m	m	У	У	У	У	

Has the participant developed any NEW co-morbidities (which were not recorded in any previous CRFs)? (please tick all that apply in the tables below and overleaf)

Myocardial infarct	
Angina/coronary artery disease	
Congestive Heart Failure	
Cardiac Arrythmias	
Hypertension	
Venous Disease (PE/DVT)	
Peripheral Arterial Disease	
Restrictive Lung Disease or COPD (chronic bronchitis, emphysema, asthma etc.)	
Liver Disease (portal hypertension, chronic/acute hepatitis, cirrhosis etc.)	
Stomach Ulcers or Inflammatory Bowel Disease	
Acute or Chronic Pancreatitis	
End-stage Renal Disease (chronic renal insufficiency, dialysis etc.)	
Thyroid problems (hyperthyroidism, hypothyroidism etc.)	
Diabetes Mellitus Type 1	
Diabetes Mellitus Type 2	
Stroke/TIA	
Dementia	
Paralysis (paraplegia or hemiplegia)	
Neuromuscular Condition (multiple sclerosis, Parkinson's, myasthenia gravis, other chronic neuromuscular disorder)	
Clinical diagnosis of anxiety	

Clinical diagnosis of depression	
Psychiatric Diagnosis (e.g. schizophrenia, bipolar disorder)	
Osteoarthritis	
Rheumatoid Arthritis	
Other Rheumatological Disease (systemic lupus, mixed connective tissue disorder, polymyositis, rheumatic polymyositis, scleroderma etc.)	
HIV/AIDS	
Alcohol Abuse (or history of, must be accompanied by social, behavioural or medical com-	

Drug/Substance Abuse (or history of, must be accompanied by social, behavioural or

Other (please give details)

Other (please give details)

Other (please give details) _____

Participant's Study ID

plications)

medical complications)

Morbid Obesity

Is the participant pre or post me	enopause? (p	lease tick one box)
Pre menopause		
Post menopause		
Unknown		

Participant's Study ID

What treatments has the participant received **since those captured in any previous CRFs**, please tick ALL that apply and write details in the spaces provided. Please add end dates for any treatments which were ongoing previously (table continued overleaf).

Treatment type	Specific treatment details	Tick if patient has received	Date of surgery or start date of other treatment (dd/mm/yyyy)	End date of treatment (if finished) (dd/mm/yyyy)	If course of treatment was not completed as planned, please give a reason why	
Surgery	Please give details below of surgery (e.g. surgery for cancer, palliative surgery)		// 20			
Radiotherapy	Number of radiotherapy fractions, please enter on line Dose for each radiotherapy fraction please enter on line					
Hormone Therapy	please give details below		//20	//20		

Participant's Study ID	/	/	

Treatment type	Specific treatment details	Tick if patient has received	Date of surgery or start date of other treatment (dd/mm/yyyy)	End date of treatment (if finished) (dd/mm/yyyy)	If course of treatment was not completed as planned, please give a reason why
Chemotherapy	Drug(s), please tick all that apply				
	Carboplatin		//20	//20	
	Weekly Paclitaxel		// 20	// 20	
	Three Weekly Paclitaxel		//20	// 20	
	Abraxane (Paclitaxel protein bound)		//20	// 20	
	Liposomal doxorubicin		//20	//20	
	Docetaxel		//20	// 20	
	Gemcitabine		//20	// 20	
	Topotecan		//20	// 20	
	Etoposide		//20	// 20	
	Cyclophosphamide		//20	// 20	
	Other (please describe below):		// 20	// 20	
	Chemotherapy number of	cycles, plea	se enter on line		
Maintenance Treatment	Please give details of any drugs used as maintenance therapy		//20	//20	
Additional Treatment	If any additional treatment has been given please describe		//20	// 20	

Participant's Study ID / /
Were any of the treatments detailed given with palliative intent?
(please tick one box) Yes No Unknown
If yes, please indicate which treatments?
Has the participant had a local recurrence of their ovarian, primary peritoneal or fallopian tube cancer? (please tick one box) Yes No Unknown
If the participant has had a local recurrence, on what date was the recurrence
diagnosed?
Since the participant's diagnosis of their ovarian, primary peritoneal or fallopian tube cancer, has there been any evidence of distant metastatic disease? (please tick one box)
Yes No Unknown
If you have answered "yes" to the above question, on what date was the metastatic disease diagnosed:
d d m m y y y y
Please provide details of the site(s) of distant metastatic disease:
Is the participant taking part in a clinical trial? (please tick one box)
Yes Unknown
If you answered "yes" to the above question, please give the NAME of the clinical trial the participant is taking part in
Name of clinical trial

Participant's Study ID /					
Since the participant's diagnosis of ovariar cancer, have they been diagnosed with and box)	n, primary peritoneal or fallopian tube other new primary cancer? (please tick one				
Yes No	Unknown				
If you answered "yes" to the above question, please provide some information about the participant's new cancer diagnosis by completing the table below					
Type of cancer					
Date of diagnosis	// 20				
Treatment received					
Date treatment ended (if finished)	// 20				
What type of follow-up care is the participant receiving? (please tick ONE box)					
Routine/regular hospital clinic based follow-up (medical or nurse led, face-to-face or by telephone)					
Primary care based follow-up					
Patient initiated follow-up (also known as patient triggered follow-up (PTFU), open access follow-up, or supported self-managed follow-up)					
If the participant is receiving patient-initiated follow-up, on what date were they discharged to this?					

Participant's Study ID / /	
Has the participant been referred to any of the following services and/or had a Holistic Needs Assessment? (please tick all that apply)	
Participant has been referred to palliative care services	
If available, please give reason for referral (e.g. end of life care, symptom management)	
Participant has been referred to psychological services	
If ticked, please provide route to referral (e.g. GP, Improving Access to Psychological Therapies)	
Participant has been referred to community services	
Participant has been referred for treatment related problems (e.g. urology, gastroenterology) If ticked, please provide more details below:	
Participant has had an HNA (holistic needs assessment)	
If the participant has died please give the date and cause of death: Participant's date of death d d m m / y y y y Cause of participant's death	
1) a)	
1) b)	
1) c)	
2)	
Cause of death not known	
Please add your name and signature and the date that you completed this CRF	
Name Signature	
Date CRE completed dd / m m / y y y y	